| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1000828240 |
| P356 | DOI | 10.1007/S11302-011-9216-0 |
| P932 | PMC publication ID | 3166987 |
| P698 | PubMed publication ID | 21484092 |
| P5875 | ResearchGate publication ID | 51042845 |
| P50 | author | Stefano Costanzi | Q37381929 |
| Kenneth A. Jacobson | Q37387267 | ||
| P2093 | author name string | Francesca Deflorian | |
| Shilpi Mishra | |||
| P2860 | cites work | Identification of the platelet ADP receptor targeted by antithrombotic drugs | Q24290845 |
| Trimeric architecture of homomeric P2X2 and heteromeric P2X1+2 receptor subtypes | Q24301398 | ||
| Site-directed mutagenesis identifies residues involved in ligand recognition in the human A2a adenosine receptor | Q24612312 | ||
| International Union of Pharmacology LVIII: update on the P2Y G protein-coupled nucleotide receptors: from molecular mechanisms and pathophysiology to therapy | Q24629255 | ||
| The 2.6 angstrom crystal structure of a human A2A adenosine receptor bound to an antagonist | Q24654563 | ||
| Crystal structure of the ATP-gated P2X(4) ion channel in the closed state | Q24657193 | ||
| The orphan receptor GPR17 identified as a new dual uracil nucleotides/cysteinyl-leukotrienes receptor | Q24672638 | ||
| Beta-nicotinamide adenine dinucleotide is an inhibitory neurotransmitter in visceral smooth muscle | Q24673894 | ||
| A novel P2Y(12) adenosine diphosphate receptor antagonist that inhibits platelet aggregation and thrombus formation in rat and dog models | Q28222823 | ||
| The adenosine a2b receptor: its role in inflammation | Q28303755 | ||
| Methanocarba modification of uracil and adenine nucleotides: high potency of Northern ring conformation at P2Y1, P2Y2, P2Y4, and P2Y11 but not P2Y6 receptors | Q28344116 | ||
| Antiplatelet action of R-99224, an active metabolite of a novel thienopyridine-type G(i)-linked P2T antagonist, CS-747 | Q28345809 | ||
| Selectivity of diadenosine polyphosphates for rat P2X receptor subunits | Q28371849 | ||
| Second messenger cascade specificity and pharmacological selectivity of the human P2Y1-purinoceptor | Q28637757 | ||
| Structure-based discovery of novel chemotypes for adenosine A(2A) receptor antagonists | Q30435017 | ||
| Adenosine 5'-O-(1-boranotriphosphate) derivatives as novel P2Y(1) receptor agonists. | Q30746442 | ||
| NF449 is a novel inhibitor of fibroblast growth factor receptor 3 (FGFR3) signaling active in chondrocytes and multiple myeloma cells | Q30982341 | ||
| Applying the pro-drug approach to afford highly bioavailable antagonists of P2Y(14). | Q31019114 | ||
| Inhibition of platelet function by administration of MRS2179, a P2Y1 receptor antagonist | Q31882653 | ||
| MRS2500 [2-iodo-N6-methyl-(N)-methanocarba-2'-deoxyadenosine-3',5'-bisphosphate], a potent, selective, and stable antagonist of the platelet P2Y1 receptor with strong antithrombotic activity in mice | Q33225547 | ||
| Piperazinyl-glutamate-pyridines as potent orally bioavailable P2Y12 antagonists for inhibition of platelet aggregation | Q33482579 | ||
| PEGylated dendritic unimolecular micelles as versatile carriers for ligands of G protein-coupled receptors | Q33507142 | ||
| Piperazinyl glutamate pyridines as potent orally bioavailable P2Y12 antagonists for inhibition of platelet aggregation | Q33530193 | ||
| Structure-based discovery of A2A adenosine receptor ligands | Q33560239 | ||
| Human P2Y(14) receptor agonists: truncation of the hexose moiety of uridine-5'-diphosphoglucose and its replacement with alkyl and aryl groups | Q33584104 | ||
| Defective platelet aggregation and increased resistance to thrombosis in purinergic P2Y(1) receptor-null mice | Q33903557 | ||
| Charged residues in the C-terminus of the P2Y1 receptor constitute a basolateral-sorting signal | Q33951253 | ||
| Novel Alexa Fluor-488 labeled antagonist of the A(2A) adenosine receptor: Application to a fluorescence polarization-based receptor binding assay | Q33976371 | ||
| Functionalized congeners of P2Y1 receptor antagonists: 2-alkynyl (N)-methanocarba 2'-deoxyadenosine 3',5'-bisphosphate analogues and conjugation to a polyamidoamine (PAMAM) dendrimer carrier | Q34029528 | ||
| P2Y nucleotide receptors: promise of therapeutic applications | Q34062142 | ||
| Mutational analysis of residues important for ligand interaction with the human P2Y(12) receptor | Q34169728 | ||
| Activation of P2Y1 nucleotide receptors induces inhibition of the M-type K+ current in rat hippocampal pyramidal neurons | Q41961727 | ||
| Diinosine pentaphosphate (IP5I) is a potent antagonist at recombinant rat P2X1 receptors. | Q42085394 | ||
| Specificity of the ecto-ATPase inhibitor ARL 67156 on human and mouse ectonucleotidases | Q42133085 | ||
| Inter-subunit disulfide cross-linking in homomeric and heteromeric P2X receptors | Q42166779 | ||
| Trinitrophenyl-substituted nucleotides are potent antagonists selective for P2X1, P2X3, and heteromeric P2X2/3 receptors. | Q42541961 | ||
| Identification of competitive antagonists of the P2Y1 receptor. | Q42552594 | ||
| Identification of a receptor for ADP on blood platelets by photoaffinity labelling | Q42796937 | ||
| Agonist and antagonist effects of diadenosine tetraphosphate, a platelet dense granule constituent, on platelet P2Y1, P2Y12 and P2X1 receptors. | Q42909234 | ||
| Benzofuran-substituted urea derivatives as novel P2Y(1) receptor antagonists | Q43027762 | ||
| A new role for the A2b adenosine receptor in regulating platelet function | Q43183880 | ||
| Part II: piperazinyl-glutamate-pyridines as potent orally bioavailable P2Y12 antagonists for inhibition of platelet aggregation | Q43185318 | ||
| Comparison of ticagrelor and thienopyridine P2Y(12) binding characteristics and antithrombotic and bleeding effects in rat and dog models of thrombosis/hemostasis | Q43289595 | ||
| Interaction of new, very potent non-nucleotide antagonists with Arg256 of the human platelet P2Y12 receptor | Q43290040 | ||
| Novel tricyclic benzothiazolo[2,3-c]thiadiazine antagonists of the platelet ADP receptor (P2Y(12)). | Q43679810 | ||
| Activity of diadenosine polyphosphates at P2Y receptors stably expressed in 1321N1 cells | Q43800933 | ||
| A general approach toward the synthesis of C-nucleoside pyrazolo[1,5-a]-1,3,5-triazines and their 3',5'-bisphosphate C-nucleotide analogues as the first reported in vivo stable P2Y(1)-receptor antagonists | Q44210114 | ||
| The hypolipidemic drug metabolites nafenopin-CoA and ciprofibroyl-CoA are competitive P2Y1 receptor antagonists | Q44314960 | ||
| Purification and Functional Reconstitution of the Human P2Y12Receptor | Q44628575 | ||
| Agonist binding and Gq-stimulating activities of the purified human P2Y1 receptor | Q44741503 | ||
| Synthesis and biological activity of 2-alkylated deoxyadenosine bisphosphate derivatives as P2Y(1) receptor antagonists | Q44803614 | ||
| Arg333 and Arg334 in the COOH terminus of the human P2Y1 receptor are crucial for Gq coupling | Q45127883 | ||
| Interaction of the active metabolite of prasugrel, R-138727, with cysteine 97 and cysteine 175 of the human P2Y12 receptor | Q45140487 | ||
| Biochemical and functional evidence for heteromeric assembly of P2X1 and P2X4 subunits | Q45247897 | ||
| Profiling at recombinant homomeric and heteromeric rat P2X receptors identifies the suramin analogue NF449 as a highly potent P2X1 receptor antagonist | Q45274145 | ||
| Novel P2Y12 adenosine diphosphate receptor antagonists for inhibition of platelet aggregation (I): in vitro effects on platelets | Q45300057 | ||
| Ticagrelor binds to human P2Y(12) independently from ADP but antagonizes ADP-induced receptor signaling and platelet aggregation. | Q45954831 | ||
| 6-Amino-2-mercapto-3H-pyrimidin-4-one derivatives as new candidates for the antagonism at the P2Y12 receptors. | Q45999081 | ||
| High-affinity, non-nucleotide-derived competitive antagonists of platelet P2Y12 receptors. | Q46000448 | ||
| Tetrahydro-4-quinolinamines identified as novel P2Y(1) receptor antagonists | Q46312937 | ||
| Effects of 5'-phosphate derivatives of 2-hexynyl adenosine and 2-phenylethynyl adenosine on responses of human platelets mediated by P2Y receptors. | Q46436392 | ||
| P2Y1 receptor antagonists as novel antithrombotic agents | Q46620039 | ||
| The novel suramin analogue NF864 selectively blocks P2X1 receptors in human platelets with potency in the low nanomolar range | Q46699751 | ||
| Acyl derivatives of coenzyme A inhibit platelet function via antagonism at P2Y1 and P2Y12 receptors: a new finding that may influence the design of anti-thrombotic agents | Q46735701 | ||
| Synthesis and preliminary evaluation of [3H]PSB-0413, a selective antagonist radioligand for platelet P2Y12 receptors | Q46743054 | ||
| Carba-nucleosides as potent antagonists of the adenosine 5'-diphosphate (ADP) purinergic receptor (P2Y12 on human platelets | Q46788165 | ||
| Pharmacological characterization of recombinant human and rat P2X receptor subtypes | Q48911279 | ||
| Antagonistic properties of the suramin analogue NF023 at heterologously expressed P2X receptors | Q48921231 | ||
| P2-purinoceptor antagonists: II. Blockade of P2-purinoceptor subtypes and ecto-nucleotidases by compounds related to Evans blue and trypan blue. | Q50535582 | ||
| The suramin analogue NF279 is a novel and potent antagonist selective for the P2X(1) receptor. | Q50724270 | ||
| BF0801, a novel adenine derivative, inhibits platelet activation via phosphodiesterase inhibition and P2Y12 antagonism | Q51772011 | ||
| Stereoselective inhibition of human platelet aggregation by R-138727, the active metabolite of CS-747 (prasugrel, LY640315), a novel P2Y12 receptor inhibitor. | Q51812620 | ||
| Homozygous type I Protein C deficiency in neonatal purpura fulminans with a novel frame-shift deletion of 10 base pairs in exon 8 of PROC gene. | Q53625568 | ||
| Molecular recognition of modified adenine nucleotides by the P2Y(1)-receptor. 1. A synthetic, biochemical, and NMR approach. | Q55476249 | ||
| Detection of P2Y(14) protein in platelets and investigation of the role of P2Y(14) in platelet function in comparison with the EP(3) receptor | Q58616257 | ||
| Identification and biological activity of the active metabolite of clopidogrel | Q73322574 | ||
| Antagonists of the platelet P2T receptor: a novel approach to antithrombotic therapy | Q77928203 | ||
| Defining the nucleotide binding sites of P2Y receptors using rhodopsin-based homology modeling | Q79177476 | ||
| Mitochondrial calcium transport is regulated by P2Y1- and P2Y2-like mitochondrial receptors | Q79776887 | ||
| P2Y1 antagonists: combining receptor-based modeling and QSAR for a quantitative prediction of the biological activity based on consensus scoring | Q80468482 | ||
| Rapid and reversible modulation of platelet function in man by a novel P2Y(12) ADP-receptor antagonist, INS50589 | Q80677617 | ||
| From ATP to AZD6140: the discovery of an orally active reversible P2Y12 receptor antagonist for the prevention of thrombosis | Q81161941 | ||
| Inhibition of receptor/G protein coupling by suramin analogues. | Q34388145 | ||
| Molecular basis for ADP-induced platelet activation. II. The P2Y1 receptor mediates ADP-induced intracellular calcium mobilization and shape change in platelets | Q34453608 | ||
| Inactivation of the human P2Y12 receptor by thiol reagents requires interaction with both extracellular cysteine residues, Cys17 and Cys270. | Q34530924 | ||
| Ebselen is a potent non-competitive inhibitor of extracellular nucleoside diphosphokinase | Q34551159 | ||
| Adenosine receptor antagonists: translating medicinal chemistry and pharmacology into clinical utility | Q34734061 | ||
| Differential effects of P2-purinoceptor antagonists on phospholipase C- and adenylyl cyclase-coupled P2Y-purinoceptors | Q34792562 | ||
| Purine and pyrimidine (P2) receptors as drug targets | Q34815266 | ||
| Structure-activity relationships of suramin and pyridoxal-5'-phosphate derivatives as P2 receptor antagonists | Q34947219 | ||
| New P2Y12 antagonists | Q34988595 | ||
| [32P]2-iodo-N6-methyl-(N)-methanocarba-2'-deoxyadenosine-3',5'-bisphosphate ([32P]MRS2500), a novel radioligand for quantification of native P2Y1 receptors | Q35100653 | ||
| Activation and regulation of purinergic P2X receptor channels | Q35122793 | ||
| Quantitation of the P2Y(1) receptor with a high affinity radiolabeled antagonist | Q35200801 | ||
| 2,2'-Pyridylisatogen tosylate antagonizes P2Y1 receptor signaling without affecting nucleotide binding | Q35213075 | ||
| Identification of potent, selective P2Y-purinoceptor agonists: structure-activity relationships for 2-thioether derivatives of adenosine 5'-triphosphate | Q35606305 | ||
| Emerging roles for P2X1 receptors in platelet activation | Q35809098 | ||
| Potent agonist action of 2-thioether derivatives of adenine nucleotides at adenylyl cyclase-linked P2Y-purinoceptors | Q35873053 | ||
| Identification of potent P2Y-purinoceptor agonists that are derivatives of adenosine 5'-monophosphate | Q35874099 | ||
| Comparative studies on the affinities of ATP derivatives for P2x-purinoceptors in rat urinary bladder | Q35874677 | ||
| Purification and Recognition of Recombinant Mouse P2X(1) Receptors Expressed in a Baculovirus System | Q36058000 | ||
| Activity of Novel Adenine Nucleotide Derivatives as Agonists and Antagonists at Recombinant Rat P2X Receptors | Q36086811 | ||
| Northern Ring Conformation of Methanocarba-Adenosine 5'-Triphosphate Required for Activation of P2X Receptors. | Q36108563 | ||
| 2-Substitution of Adenine Nucleotide Analogues Containing a Bicyclo[3.1.0]hexane Ring System Locked in a Northern Conformation: Enhanced Potency as P2Y1 Receptor Antagonists | Q36128578 | ||
| (N)-methanocarba-2MeSADP (MRS2365) is a subtype-specific agonist that induces rapid desensitization of the P2Y1 receptor of human platelets | Q36147741 | ||
| Glutamate residues in the second extracellular loop of the human A2a adenosine receptor are required for ligand recognition | Q36183047 | ||
| Architecture of P2Y nucleotide receptors: structural comparison based on sequence analysis, mutagenesis, and homology modeling. | Q36201452 | ||
| Modelling the P2Y purinoceptor using rhodopsin as template | Q36251014 | ||
| The role of amino acids in extracellular loops of the human P2Y1 receptor in surface expression and activation processes. | Q36253724 | ||
| Induction of novel agonist selectivity for the ADP-activated P2Y1 receptor versus the ADP-activated P2Y12 and P2Y13 receptors by conformational constraint of an ADP analog. | Q36282943 | ||
| Human P2Y1 receptor: molecular modeling and site-directed mutagenesis as tools to identify agonist and antagonist recognition sites. | Q36311516 | ||
| Antiaggregatory activity in human platelets of potent antagonists of the P2Y 1 receptor. | Q36316891 | ||
| Quantification of recombinant and platelet P2Y(1) receptors utilizing a [(125)I]-labeled high-affinity antagonist 2-iodo-N(6)-methyl-(N)-methanocarba-2'-deoxyadenosine-3',5'-bisphosphate ([(125)I]MRS2500) | Q36626943 | ||
| Caged agonist of P2Y1 and P2Y12 receptors for light-directed facilitation of platelet aggregation. | Q36632204 | ||
| Adenine nucleotide analogues locked in a Northern methanocarba conformation: enhanced stability and potency as P2Y(1) receptor agonists | Q37122033 | ||
| Quantification of Gi-mediated inhibition of adenylyl cyclase activity reveals that UDP is a potent agonist of the human P2Y14 receptor | Q37444485 | ||
| Ticagrelor: the first reversibly binding oral P2Y12 receptor antagonist | Q37552005 | ||
| Recent developments in adenosine A2A receptor ligands | Q37565154 | ||
| New P2Y(12) inhibitors | Q37667399 | ||
| Elinogrel, a reversible P2Y12 receptor antagonist for the treatment of acute coronary syndrome and prevention of secondary thrombotic events. | Q37697100 | ||
| P2X purinergic receptor ligands: recently patented compounds | Q37703255 | ||
| Physiological implications of adenosine receptor-mediated platelet aggregation | Q37780716 | ||
| Ectonucleotidases as regulators of purinergic signaling in thrombosis, inflammation, and immunity | Q37876541 | ||
| Transient expression of the recombinant chick brain P2y1 purinoceptor and localization of the corresponding mRNA. | Q38468312 | ||
| ADP ribose is an endogenous ligand for the purinergic P2Y1 receptor. | Q39629251 | ||
| 2-MeS-beta,gamma-CCl2-ATP is a potent agent for reducing intraocular pressure | Q39722931 | ||
| A novel insulin secretagogue based on a dinucleoside polyphosphate scaffold | Q39736692 | ||
| Development of potent and selective inhibitors of ecto-5'-nucleotidase based on an anthraquinone scaffold | Q39741301 | ||
| Extracellular NAD(+) induces a rise in [Ca(2+)](i) in activated human monocytes via engagement of P2Y(1) and P2Y(11) receptors | Q39800524 | ||
| Involvement of basic amino acid residues in transmembrane regions 6 and 7 in agonist and antagonist recognition of the human platelet P2Y(12)-receptor | Q39937155 | ||
| Identification of hydrolytically stable and selective P2Y(1) receptor agonists. | Q39945033 | ||
| Rapid resensitization of purinergic receptor function in human platelets. | Q39976986 | ||
| Constitutive and agonist-induced dimerizations of the P2Y1 receptor: relationship to internalization and scaffolding. | Q40013918 | ||
| Lipophilic modifications to dinucleoside polyphosphates and nucleotides that confer antagonist properties at the platelet P2Y12 receptor | Q40018963 | ||
| Hetero-oligomerization of the P2Y11 receptor with the P2Y1 receptor controls the internalization and ligand selectivity of the P2Y11 receptor | Q40083620 | ||
| Synthesis and structure-activity relationships of suramin-derived P2Y11 receptor antagonists with nanomolar potency | Q40357842 | ||
| Identification of a potent inverse agonist at a constitutively active mutant of human P2Y12 receptor | Q40360423 | ||
| Discovery and synthesis of a novel and selective drug-like P2X(1) antagonist | Q40415070 | ||
| Acyclic analogues of adenosine bisphosphates as P2Y receptor antagonists: phosphate substitution leads to multiple pathways of inhibition of platelet aggregation. | Q40684082 | ||
| Structure-activity relationships of dinucleotides: Potent and selective agonists of P2Y receptors. | Q40722376 | ||
| Structure-activity relationships of pyridoxal phosphate derivatives as potent and selective antagonists of P2X1 receptors | Q40791305 | ||
| A pyridoxine cyclic phosphate and its 6-azoaryl derivative selectively potentiate and antagonize activation of P2X1 receptors | Q40854824 | ||
| Structure-activity relationships of bisphosphate nucleotide derivatives as P2Y1 receptor antagonists and partial agonists. | Q40956148 | ||
| Co-expression of P2X1 and P2X5 receptor subunits reveals a novel ATP-gated ion channel. | Q40987897 | ||
| Contribution of the region Glu181 to Val200 of the extracellular loop of the human P2X1 receptor to agonist binding and gating revealed using cysteine scanning mutagenesis. | Q41502656 | ||
| Heteromultimeric P2X(1/2) receptors show a novel sensitivity to extracellular pH | Q41569539 | ||
| A multiple dose study of prasugrel (CS-747), a novel thienopyridine P2Y12 inhibitor, compared with clopidogrel in healthy humans | Q41868121 | ||
| P433 | issue | 3 | |
| P304 | page(s) | 305-324 | |
| P577 | publication date | 2011-02-18 | |
| P1433 | published in | Purinergic Signalling | Q15716545 |
| P1476 | title | Pharmacochemistry of the platelet purinergic receptors | |
| P478 | volume | 7 |
| Q45369986 | 4-Benzothiazole-7-hydroxyindolinyl diaryl ureas are potent P2Y1 antagonists with favorable pharmacokinetics: low clearance and small volume of distribution |
| Q28537750 | Antiplatelet activity, P2Y₁ and P2Y₁₂ inhibition, and metabolism in plasma of stereoisomers of diadenosine 5',5'″-P¹ ,P⁴-dithio-P²,P³-chloromethylenetetraphosphate |
| Q34217242 | Better detection of platelet aggregation in patients with metabolic syndrome using epinephrine and ADP. |
| Q26799623 | Blood cells: an historical account of the roles of purinergic signalling |
| Q35168275 | Comparison of three GPCR structural templates for modeling of the P2Y12 nucleotide receptor |
| Q46252915 | Demystifying P2Y1 Receptor Ligand Recognition through Docking and Molecular Dynamics Analyses |
| Q64969552 | Does the lipid bilayer orchestrate access and binding of ligands to transmembrane orthosteric/allosteric sites of GPCRs? |
| Q42645486 | Identification of a Different Agonist-Binding Site and Activation Mechanism of the Human P2Y1 Receptor |
| Q42096462 | Ligand binding to a G protein-coupled receptor captured in a mass spectrometer |
| Q27316009 | Modeling ligand recognition at the P2Y12 receptor in light of X-ray structural information |
| Q36359617 | New highly active antiplatelet agents with dual specificity for platelet P2Y1 and P2Y12 adenosine diphosphate receptors |
| Q28264649 | P2Y12 receptors: structure and function |
| Q34154991 | Pericellular pH homeostasis is a primary function of the Warburg effect: inversion of metabolic systems to control lactate steady state in tumor cells |
| Q93017246 | Recent Insights from Molecular Dynamics Simulations for G Protein-Coupled Receptor Drug Discovery |
| Q34989717 | Single nucleotide polymorphism network: a combinatorial paradigm for risk prediction |
| Q38061149 | The discovery of a new class of synaptic transmitters in smooth muscle 50 years ago and amelioration of coronary artery thrombosis |
| Q34469331 | Two disparate ligand-binding sites in the human P2Y1 receptor |
Search more.